Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | UBE2D3 | P61077 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8720626 | 0.92 | MAPT (0.58) | GAAMAPTMAPK1HTTALDH1A1 | |
| SCHEMBL1682765 | 0.92 | MAPT (0.58) | GAAMAPTMAPK1HTTALDH1A1 | |
| SCHEMBL29711503 | 0.88 | GAA (0.55) | GAAMAPTMAPK1HTTALDH1A1 | |
| SCHEMBL29627140 | 0.73 | GAA (1.00) | GAAMAPTMAPK1HTTCYP19A1 | |
| SCHEMBL27930878 | 0.73 | GAA (1.00) | GAAMAPTMAPK1HTTCYP19A1 | |
| SCHEMBL30252306 | 0.62 | CYP19A1 (0.52) | MAPTMAPK1HTTALDH1A1CYP19A1 | |
| SCHEMBL30741430 | 0.61 | ALDH1A1 (0.70) | MAPTMAPK1HTTALDH1A1CYP19A1 | |
| SCHEMBL29372890 | 0.61 | ALDH1A1 (0.67) | MAPTMAPK1HTTALDH1A1CYP19A1 | |
| SCHEMBL29756636 | 0.60 | NPC1 (0.60) | MAPTMAPK1HTTALDH1A1CYP19A1 | |
| Dehydroleucodin SCHEMBL4998391 | 0.60 | CYP19A1 (1.00) | MAPTMAPK1HTTALDH1A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-20180360974-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2018-12-20 | — | — | US | disclosed |
| WO-2018163131-A1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2018-09-13 | — | — | WO | disclosed |
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
| EP-2841109-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | Ascendis Pharma A/S (DK) | 2015-03-04 | — | — | EP | disclosed |
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-20140243254-A1 | Polymeric Hyperbranched Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-08-28 | — | — | US | disclosed |
| EP-2741779-A1 | HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS | Ascendis Pharma A/S (DK) | 2014-06-18 | — | — | EP | disclosed |
| EP-2741778-A1 | POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | Ascendis Pharma A/S (DK) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013160340-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013024048-A1 | POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024047-A1 | HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| US-5801254-A | TREATMENT OF CANCER AND ANGIOGENESIS-RELATED DISEASES | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1998-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ABCB11, SLCO1B1, SLC7A1 | GAA 407/4885MAPT 1533/4885MAPK1 1583/4885 |
| US-20180360974-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | GAA 12/4885MAPT 3354/4885MAPK1 4622/4885 |
| US-20140243254-A1 | Polymeric Hyperbranched Carrier-Linked Prodrugs | P4HA1, CYP8B1, PAH | GAA 280/4885MAPT 905/4885MAPK1 2889/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | GAA 12/4885MAPT 3354/4885MAPK1 4622/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | GAA 12/4885MAPT 3354/4885MAPK1 4622/4885 |
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ABCB1, CYP2D6, LDHA | GAA 618/4885MAPT 4542/4885MAPK1 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.